Investigation of the Diurnal Variation in Bone Resorption for Optimal Drug Delivery and Efficacy in Osteoporosis with Oral Calcitonin

Overview

Journal BMC Clin Pharmacol

Publisher Biomed Central

Specialty Pharmacology

Date 2008 Dec 6

PMID 19055791

Citations 17

Authors

M A Karsdal

I Byrjalsen

B J Riis

C Christiansen

Affiliations

Soon will be listed here.

Abstract

Background: Bone resorption displays marked diurnal variation. Reversible inhibition of bone resorption may result in best possible efficacy when bone resorption peaks. The aim of the study was to assess the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of 0.8 mg of oral salmon calcitonin (sCT) and the effect of timing of drug intake.

Methods: The study was a randomized, double-blind, double-dummy, placebo-controlled, phase I study to assess the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of 0.8 mg of oral sCT in healthy postmenopausal women. Totally 81 subjects were included, aimed at investigation of a morning dose given at 8:00 (n = 42), a pre-dinner dose given at 17:00 (n = 20), and an evening dose given at 22:00 (n = 19). Plasma sCT concentrations and bone resorption (C-terminal-telopeptide of collagen type I (CTX-I)) was assessed.

Results: Morning and pre-dinner dosing led to comparable concentration of sCT of 45 pg/ml, whereas there was a tendency towards lower Cmax for the evening dosing having a mean of 24 pg/ml. The maximum difference from placebo was observed 1 to 3 hours post-dose with a 40 to 50% suppression consequent to morning dose, and about 75% suppression after pre-dinner and evening dose, due to the increase bone resorption as a result of circadian variation.

Conclusion: The study suggests that orally administered 0.8 mg of salmon calcitonin was effective in suppression of serum CTX irrespective of time of dosing. The pre-dinner dosing resulted in optimum efficacy response corresponding to an overall suppression of bone resorption by 25%.

Citing Articles

Circadian Regulation of Endocrine Fibroblast Growth Factors on Systemic Energy Metabolism.

Yang Z, Zarbl H, Guo G Mol Pharmacol. 2024; 105(3):179-193.

PMID: 38238100 PMC: 10877735. DOI: 10.1124/molpharm.123.000831.

The role of circadian rhythm in osteoporosis; a review.

Tian Y, Ming J Front Cell Dev Biol. 2022; 10:960456.

PMID: 36238690 PMC: 9550872. DOI: 10.3389/fcell.2022.960456.

Calcitonin (FORTICAL, MIACALCIN) for the treatment of vertebral compression fractures.

Kaneb A, Berardino K, Hanukaai J, Rooney K, Kaye A Orthop Rev (Pavia). 2021; 13(2):24976.

PMID: 34745472 PMC: 8567816. DOI: 10.52965/001c.24976.

Chronobiology and Chronotherapy of Osteoporosis.

Winter E, Kooijman S, Appelman-Dijkstra N, Meijer O, Rensen P, Schilperoort M JBMR Plus. 2021; 5(10):e10504.

PMID: 34693186 PMC: 8520066. DOI: 10.1002/jbm4.10504.

A biomarker perspective on the acute effect of exercise with and without impact on joint tissue turnover: an exploratory randomized cross-over study.

Bjerre-Bastos J, Nielsen H, Andersen J, Karsdal M, Boesen M, Mackey A Eur J Appl Physiol. 2021; 121(10):2799-2809.

PMID: 34156534 DOI: 10.1007/s00421-021-04751-z.

References

Shareef M, Khar R, Ahuja A, Ahmad F, Raghava S . Colonic drug delivery: an updated review. AAPS PharmSci. 2003; 5(2):E17. DOI: 10.1208/ps050217. View

Mustata G, Dinh S . Approaches to oral drug delivery for challenging molecules. Crit Rev Ther Drug Carrier Syst. 2006; 23(2):111-35. DOI: 10.1615/critrevtherdrugcarriersyst.v23.i2.20. View

Garcia-Fuentes M, Torres D, Alonso M . New surface-modified lipid nanoparticles as delivery vehicles for salmon calcitonin. Int J Pharm. 2005; 296(1-2):122-32. DOI: 10.1016/j.ijpharm.2004.12.030. View

Karsdal M, Martin T, Bollerslev J, Christiansen C, Henriksen K . Are nonresorbing osteoclasts sources of bone anabolic activity?. J Bone Miner Res. 2007; 22(4):487-94. DOI: 10.1359/jbmr.070109. View

Bjarnason N, Henriksen E, Alexandersen P, Christgau S, Henriksen D, Christiansen C . Mechanism of circadian variation in bone resorption. Bone. 2002; 30(1):307-13. DOI: 10.1016/s8756-3282(01)00662-7. View

Lee Y, Sinko P . Oral delivery of salmon calcitonin. Adv Drug Deliv Rev. 2000; 42(3):225-38. DOI: 10.1016/s0169-409x(00)00063-6. View

Guggi D, Kast C, Bernkop-Schnurch A . In vivo evaluation of an oral salmon calcitonin-delivery system based on a thiolated chitosan carrier matrix. Pharm Res. 2004; 20(12):1989-94. DOI: 10.1023/b:pham.0000008047.82334.7d. View

Wang J, Chow D, Heiati H, Shen W . Reversible lipidization for the oral delivery of salmon calcitonin. J Control Release. 2003; 88(3):369-80. DOI: 10.1016/s0168-3659(03)00008-7. View

Schlemmer A, Hassager C, Jensen S, Christiansen C . Marked diurnal variation in urinary excretion of pyridinium cross-links in premenopausal women. J Clin Endocrinol Metab. 1992; 74(3):476-80. DOI: 10.1210/jcem.74.3.1740479. View

10.

Chesnut 3rd C, Silverman S, Andriano K, Genant H, Gimona A, Harris S . A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med. 2000; 109(4):267-76. DOI: 10.1016/s0002-9343(00)00490-3. View

11.

Schaller S, Henriksen K, Sveigaard C, Heegaard A, Helix N, Stahlhut M . The chloride channel inhibitor NS3736 [corrected] prevents bone resorption in ovariectomized rats without changing bone formation. J Bone Miner Res. 2004; 19(7):1144-53. DOI: 10.1359/JBMR.040302. View

12.

Bagger Y, Tanko L, Alexandersen P, Karsdal M, Olson M, Mindeholm L . Oral salmon calcitonin induced suppression of urinary collagen type II degradation in postmenopausal women: a new potential treatment of osteoarthritis. Bone. 2005; 37(3):425-30. DOI: 10.1016/j.bone.2005.04.032. View

13.

Sakuma S, Suzuki N, Sudo R, Hiwatari K, Kishida A, Akashi M . Optimized chemical structure of nanoparticles as carriers for oral delivery of salmon calcitonin. Int J Pharm. 2002; 239(1-2):185-95. DOI: 10.1016/s0378-5173(02)00113-8. View

14.

Byrjalsen I, Leeming D, Qvist P, Christiansen C, Karsdal M . Bone turnover and bone collagen maturation in osteoporosis: effects of antiresorptive therapies. Osteoporos Int. 2007; 19(3):339-48. DOI: 10.1007/s00198-007-0462-5. View

15.

Ravn P, Hosking D, Thompson D, Cizza G, Wasnich R, McClung M . Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study. J Clin Endocrinol Metab. 1999; 84(7):2363-8. DOI: 10.1210/jcem.84.7.5847. View

16.

Sondergaard B, Oestergaard S, Christiansen C, Tanko L, Karsdal M . The effect of oral calcitonin on cartilage turnover and surface erosion in an ovariectomized rat model. Arthritis Rheum. 2007; 56(8):2674-8. DOI: 10.1002/art.22797. View

17.

Suzuki H, Nakamura I, Takahashi N, Ikuhara T, Matsuzaki K, Isogai Y . Calcitonin-induced changes in the cytoskeleton are mediated by a signal pathway associated with protein kinase A in osteoclasts. Endocrinology. 1996; 137(11):4685-90. DOI: 10.1210/endo.137.11.8895334. View

18.

Karsdal M, Qvist P, Christiansen C, Tanko L . Optimising antiresorptive therapies in postmenopausal women: why do we need to give due consideration to the degree of suppression?. Drugs. 2006; 66(15):1909-18. DOI: 10.2165/00003495-200666150-00002. View

19.

Lamprecht A, Yamamoto H, Takeuchi H, Kawashima Y . pH-sensitive microsphere delivery increases oral bioavailability of calcitonin. J Control Release. 2004; 98(1):1-9. DOI: 10.1016/j.jconrel.2004.02.001. View

20.

Sexton P, Findlay D, Martin T . Calcitonin. Curr Med Chem. 1999; 6(11):1067-93. View